Author:
Judy Gregory D.,Chera Bhishamjit S.
Publisher
Springer International Publishing
Reference13 articles.
1. Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma. Accessed 21 July 2016.
2. Lee N, Nadeem R, Ove R, Laufer Reyngold M, Foote LR, Bonner AJ. Nasopharyngeal carcinoma. Clinical radiation oncology. Philadelphia, PA: Saunders/Elsevier; 2016. p. 629–48.
3. Hara W, Loo BW Jr, Goffinet DR, et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2008;71:393–400.
4. Chen HH, Tsai ST, Wang MS, et al. Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66:1408–14.
5. Yamazaki H, Ogita M, Himei K, et al. Hypofractionated stereotactic radiotherapy using CyberKnife as a boost treatment for head and neck cancer, a multi-institutional survey: impact of planning target volume. Anticancer Res. 2014;34:5755–9.